Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Cytochroma reports positive Phase I clinical data for CTA018 Injection
July 10th, 2007
Cytochroma Inc. announced positive data from a Phase I clinical trial of CTA018 Injection. The initial top-line results from this trial showed that CTA018 was safe and well tolerated. Complete study results are expected in August 2007. The recently completed Phase I trial was an open label, placebo-controlled, randomized study of CTA018 Injection administered to 20 healthy volunteers. In this trial, the safety of CTA018 Injection was evaluated after single doses of up to 180 mcg. Placebo and two strengths of CTA018, 90 mcg and 180 mcg, were subsequently studied during repeated dose administration. The trial was conducted at a single Canadian center. Key safety...
Source: Drug Law Weekly (2007-07-10)
|
